What is the correct way to load Cerebyx (fosphenytoin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Correct Way to Load Cerebyx (Fosphenytoin)

The correct way to load Cerebyx (fosphenytoin) is to administer 18 PE/kg IV at a maximum rate of 150 PE/min for adults. 1, 2

Dosing Guidelines

Status Epilepticus

  • For status epilepticus in adults, administer a loading dose of 15-20 mg PE/kg IV at a rate of 100-150 mg PE/min 2
  • For pediatric patients with status epilepticus, administer 15-20 mg PE/kg at a rate of 2 mg PE/kg/min (or 150 mg PE/min, whichever is slower) 2
  • Intramuscular administration is not recommended for status epilepticus 2

Non-Emergent Loading and Maintenance

  • For non-emergent situations in adults, administer a loading dose of 10-20 mg PE/kg IV or IM 2
  • Initial maintenance dose is 4-6 mg PE/kg/day in divided doses 2
  • For pediatric patients, use a loading dose of 10-15 mg PE/kg at a rate of 1-2 mg PE/kg/min (or 150 mg PE/min, whichever is slower) 2

Administration Considerations

Monitoring Requirements

  • Careful cardiac monitoring is required during and after IV administration due to risk of hypotension and cardiac arrhythmias 2
  • Monitor vital signs closely, especially blood pressure and heart rate via ECG 1
  • Reduce the rate of infusion if heart rate decreases by 10 beats per minute 1

Advantages Over Phenytoin

  • Fosphenytoin can be administered faster than phenytoin (150 PE/min vs. 50 mg/min) 1, 3
  • Associated with fewer adverse events compared to IV phenytoin loading 1
  • Can be administered intramuscularly when IV access is unavailable 3
  • Fewer local reactions such as phlebitis, purple glove syndrome, and tissue necrosis 3

Common Adverse Effects

  • Transient paresthesias and pruritus may occur with rapid infusion rates 3
  • Other common adverse reactions include nystagmus, dizziness, somnolence, and ataxia 2
  • In pediatric patients, vomiting, nystagmus, and ataxia are most common 2

Special Populations

Patients with Decreased Protein Binding

  • For patients with renal or hepatic disease, hypoalbuminemia, or elderly patients, consider reducing the infusion rate by 25-50% 3
  • These patients may experience earlier and higher unbound phenytoin plasma concentrations, increasing risk of systemic adverse effects 3

Therapeutic Levels

  • After IV administration, therapeutic phenytoin levels (>10 mcg/mL) are typically achieved within minutes after completion of the infusion 1
  • After IM administration, therapeutic phenytoin levels are generally observed within 30 minutes 3
  • Higher weight-based loading doses (closer to 19 mg/kg) are more likely to achieve therapeutic levels after initial loading 4

Common Pitfalls to Avoid

  • Do not confuse the amount of drug to be given in PE with the concentration of the drug in the vial 2
  • Never exceed the maximum recommended infusion rate due to risk of severe hypotension and cardiac arrhythmias 2
  • Do not administer fosphenytoin to patients with sinus bradycardia, sino-atrial block, second and third degree A-V block, or Adams-Stokes syndrome 2
  • Avoid in patients with history of hypersensitivity to fosphenytoin, phenytoin, or hydantoins 2
  • Do not administer with solutions containing glucose as this may cause precipitation 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Dosis Recomendada de Fenitoína para el Estado Epiléptico

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.